Search the Newsreel

EyePoint Pharmaceuticals, Inc. (EYPT) options chain

This article provides detailed options chain data for EyePoint Pharmaceuticals, Inc. (EYPT) for the contract date of October 16, 2026. It lists various call and put options, including strike prices, last trade dates, last prices, implied volatility, and other relevant trading metrics. The information …

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Recommendation of "Moderate Buy" from Brokerages

Eyepoint Pharmaceuticals (NASDAQ:EYPT) has received a "Moderate Buy" consensus rating from nine brokerages, with an average 12-month price target of $44.38. Institutional ownership is high at 99.41%, with several major firms recently increasing their stakes. Despite positive analyst sentiment regarding its pipeline, the company …

Trading the Move, Not the Narrative: (EYPT) Edition

This article provides a detailed AI-driven analysis for Eyepoint Pharmaceuticals Inc. (EYPT), highlighting divergent sentiment readings and outlining specific trading strategies for various risk profiles. It identifies key support and resistance levels across multiple timeframes and suggests a significant risk-reward short setup. The analysis …

HC Wainwright Issues Negative Outlook for EYPT Earnings

EyePoint Pharma nears key Phase III data for DURAVYU in wet AMD, aiming to reduce injection frequency by 2026

EyePoint Pharmaceuticals is awaiting crucial Phase III LUGANO trial results for its wet AMD treatment, DURAVYU, which are expected by August 2026. The trial is designed to show sustained six-month dosing and compares directly to existing standard treatments. EyePoint's strong market position is bolstered …

EyePoint Pharmaceuticals Inc (EYPT) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for EyePoint Pharmaceuticals Inc (EYPT), highlighting its current earnings forecast score of 8.71 within the Pharmaceuticals industry. It details analyst ratings, price targets, and expected EPS and revenue figures. The forecast indicates a "Buy" trend based on analyst …

Eyepoint Pharmaceuticals' (EYPT) "Buy" Rating Reiterated at Chardan Capital

Chardan Capital has reiterated its "Buy" rating for Eyepoint Pharmaceuticals (NASDAQ:EYPT) and set a $65 price target, indicating a potential upside of over 400%. Despite a recent quarterly loss that missed analyst estimates, the company's revenue exceeded expectations, and institutional investors hold a significant …

RBC Capital Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT)

RBC Capital analyst Lisa Walter reiterated a Buy rating for EyePoint Pharmaceuticals (EYPT) with a price target of $37.00. This comes despite a GAAP net loss of $84.83 million in the latest quarter and negative insider sentiment with increased selling of shares. H.C. Wainwright …

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Given New $55.00 Price Target at Cantor Fitzgerald

Cantor Fitzgerald has increased its price target for Eyepoint Pharmaceuticals (NASDAQ:EYPT) to $55.00 from $47.00, maintaining an "overweight" rating and suggesting a substantial upside. This new target is part of generally positive analyst sentiment, even as the company recently reported a quarterly EPS loss …

EYPT Maintained by Cantor Fitzgerald -- Price Target Raised to $55

Cantor Fitzgerald maintained an Overweight rating for EyePoint Pharmaceuticals (EYPT) and raised its price target from $47.00 to $55.00, signaling a positive outlook despite the company's current overvaluation according to GuruFocus. EYPT's GF Value™ indicates it is significantly overvalued at $0.69 compared to its …

EyePoint, Inc. (EYPT) Stock Price, News, Quote & History

This article provides a comprehensive overview of EyePoint, Inc. (EYPT), a biotechnology company specializing in therapeutics for retinal diseases. It includes current stock price, historical performance data, key financial metrics, and analyst ratings. The company is developing treatments like DURAVYU and EYP-2301, leveraging its …

HC Wainwright Issues Pessimistic Forecast for Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Announces Quarterly Earnings Results

Ahead‑of‑Schedule DME Trial Enrollment Could Be A Game Changer For EyePoint (EYPT)

EyePoint Pharmaceuticals has completed enrollment ahead of schedule for its Phase 3 trials of DURAVYU for diabetic macular edema (DME), enrolling over 480 patients in five months. This rapid enrollment, coupled with prior safety data and regulatory alignment, positions DURAVYU as a potential long-acting …

EyePoint Pharmaceuticals Inc (EYPT) News, Articles, Events & Latest Updates

This article provides recent news and updates on EyePoint Pharmaceuticals Inc (EYPT), including its Q2 and Q1 earnings performance, analyst ratings, and insider stock transactions. It highlights EyePoint's financial results, such as beating revenue estimates in Q2 and Q1 2026, and mentions analyst consensus …

Earnings Flash (EYPT) EyePoint, Inc. Reports Q2 Revenue $507,000, vs. FactSet Est of $390,000

EyePoint, Inc. (EYPT) reported second-quarter revenue of $507,000, surpassing the FactSet estimate of $390,000. The company is a clinical-stage biopharmaceutical firm focused on developing treatments for serious retinal diseases, with its lead product candidate, DURAVYU, currently in Phase III pivotal trials for wet age-related …

EyePoint Q2 2026 earnings: Phase 3 spending widens the net loss

EyePoint (Nasdaq: EYPT) reported a widened diluted loss per share of $1.09 in Q2 2026, compared to $0.85 a year earlier, primarily due to increased spending on DURAVYU Phase 3 trials and manufacturing scale-up. Revenue significantly decreased to $0.5 million from $5.3 million, reflecting …

EYPT Looks 1591.3% Overvalued on GF Value™

EyePoint Pharmaceuticals (EYPT) is considered 1591.3% overvalued according to its GF Value™, primarily due to an extraordinary Price-to-Sales ratio of 111.19x, significantly higher than its historical median. The company, a clinical-stage biotech specializing in retinal disease treatments, is awaiting pivotal Phase 3 trial results …

[10-Q] EyePoint, Inc. Quarterly Earnings Report

Eyepoint Pharma earnings on deck ahead of pivotal trial data By Investing.com

Eyepoint Pharmaceuticals Inc. is set to release its second-quarter earnings, with investor attention primarily focused on any updates regarding its pivotal Phase 3 LUGANO trial data for Duravyu, expected in August 2026. While analysts anticipate a loss of 95 cents per share on revenue …

EyePoint Pharmaceuticals Inc (EYPT) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for EyePoint Pharmaceuticals Inc (EYPT), highlighting its current risk score of 4.82, which ranks it 80th out of 155 in the Pharmaceuticals industry. The company's beta of 1.74 indicates higher volatility compared to the S&P 500. The report …

Eyepoint Pharmaceuticals (EYPT) to Announce Quarterly Earnings on Wednesday

Eyepoint Pharmaceuticals (EYPT) is scheduled to announce its Q2 2026 earnings before market open on Wednesday, August 5th. Analysts anticipate a loss of $0.92 per share and revenue of $0.387 million. Despite missing previous earnings estimates, the stock holds a "Moderate Buy" consensus rating …

Janus Henderson Group PLC Grows Stock Position in Eyepoint Pharmaceuticals, Inc. $EYPT

EyePoint Pharmaceuticals (EYPT) Gets a Buy from Mizuho Securities

Mizuho Securities analyst Graig Suvannavejh reiterated a Buy rating on EyePoint Pharmaceuticals (EYPT) with a $39.00 price target. The company recently reported a quarterly revenue of $696 thousand and a GAAP net loss of $84.83 million, and insider sentiment is negative due to increased …

EyePoint Completes Enrollment of DURAVYU Phase 3 Trials for Diabetic Macular Edema

EyePoint Pharmaceuticals has completed enrollment for its DURAVYU Phase 3 trials (COMO and CAPRI) for diabetic macular edema (DME), enrolling over 480 participants in five months. The trials are designed as non-inferiority studies against aflibercept, focusing on DURAVYU's six-month re-dosing schedule and its distinct …

EyePoint completes enrollment in two phase 3 DME trials

EyePoint, Inc. has successfully completed enrollment in its COMO and CAPRI phase 3 clinical trials for DURAVYU, a treatment for diabetic macular edema (DME), ahead of schedule. The trials, which compare DURAVYU to aflibercept in over 480 patients, are expected to release topline data …

EYPT Looks 1669.4% Overvalued on GF Value™

EyePoint Pharmaceuticals Inc (EYPT) is significantly overvalued by 1669.4% based on its GF Value™, despite recent positive news regarding its Duravyu clinical trials. The company's high Price-to-Sales ratio of 121.35x and a modest GF Score™ of 34 out of 100 highlight weak profitability and …

EyePoint completes enrollments in Duravyu trials (EYPT:NASDAQ)

EyePoint (EYPT) announced the completion of enrollments ahead of schedule for two late-stage trials, COMO and CAPRI, for its lead asset, Duravyu. This development led to a gain in the company's shares. The company expressed confidence in the Duravyu program.

EyePoint (EYPT) Settles DOJ Claims, Is The 71% Undervaluation Case Convincing?

EyePoint (EYPT) has settled claims with the U.S. Department of Justice regarding past commercialization practices without admitting liability, agreeing to payments and a five-year Corporate Integrity Agreement. Despite recent stock declines, a prevailing narrative suggests the company is 70.6% undervalued, with a fair value …

Stempoint Capital LP Has $10.45 Million Stock Position in Eyepoint Pharmaceuticals, Inc. $EYPT

(EYPT) Volatility Zones as Tactical Triggers

This article analyzes Eyepoint Pharmaceuticals Inc. (NASDAQ: EYPT) using AI models, identifying weak near and mid-term sentiment but a neutral long-term outlook. It presents a 90.3:1 risk-reward setup targeting a 23.6% gain and outlines three institutional trading strategies: Position Trading, Momentum Breakout, and Risk …

Eyepoint $4.6M FCA Settlement

EyePoint Pharmaceuticals, Inc. has agreed to a $4.6 million settlement with the federal government, plus additional funds to states, to resolve False Claims Act allegations. The settlement addresses claims that EyePoint paid unlawful kickbacks to ambulatory surgery centers through an "Assurance Program" and excessive …

Mizuho Raises Price Target on EyePoint Pharmaceuticals to $39 From $36, Keeps Outperform Rating

Mizuho has increased its price target for EyePoint Pharmaceuticals (EYPT) to $39 from $36, while maintaining an "Outperform" rating on the stock. This adjustment reflects continued analyst confidence in the company's prospects. EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for …